Hospital Do Servidor Público Estadual - Francisco Morato de Oliveira (HSPE-FMO), Rua Pedro de Toledo 1800, São Paulo, SP, 04029000, Brazil.
CEDEP - Instituto de Assistência Médica ao Servidor Público Estadual (IAMSPE), São Paulo, Brazil.
BMC Womens Health. 2023 Sep 23;23(1):510. doi: 10.1186/s12905-023-02647-y.
Endometriosis is a chronic inflammatory disease that occurs in women of reproductive age. Much of the treatment involves hormone therapy that suppresses the proliferation of endometriosis lesions.Objective To compare discontinuation rates of pharmacological treatment with estrogen-progestins and progestins medications. The secondary objective is to evaluate the main side effects of these drugs in patients with endometriosis.Methods This retrospective study analyzed data from 330 patients who attended the Hospital of the State Public Servant of São Paulo from August 1999 to September 2020 and received pharmacological treatment for endometriosis. The data were obtained by review of the files of medical appointments with specialized staff.Results The median treatment time was 18 months, ranging from 1 to 168 months, and 177 patients interrupted the proposed treatment. The combined contraceptives with estrogens and progestins were significantly linked to treatment interruption, with a relative risk of 1,99 (p = 0,005). The most important side effects that resulted in treatment interruption were pain persistence (p = 0,043), weight gain (p = 0,017) and spotting (p < 0,001).
子宫内膜异位症是一种发生在育龄妇女中的慢性炎症性疾病。大多数治疗方法都涉及激素治疗,以抑制子宫内膜异位症病变的增殖。目的比较雌激素-孕激素和孕激素药物治疗的停药率。次要目的是评估这些药物在子宫内膜异位症患者中的主要副作用。方法本回顾性研究分析了 1999 年 8 月至 2020 年 9 月期间在圣保罗州公务员医院就诊并接受子宫内膜异位症药物治疗的 330 名患者的数据。这些数据是通过审查专门人员的医疗预约档案获得的。结果中位治疗时间为 18 个月,范围为 1 至 168 个月,177 名患者中断了所提议的治疗。含雌激素和孕激素的联合避孕药与治疗中断显著相关,相对风险为 1.99(p=0.005)。导致治疗中断的最重要副作用是疼痛持续存在(p=0.043)、体重增加(p=0.017)和点滴出血(p<0.001)。